AirSculpt Technologies (AIRS) Fundamentals 2026 — Revenue Analysis | SniperIQ
AirSculpt Technologies (AIRS) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of
AirSculpt Technologies (AIRS) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of
AirSculpt Technologies (AIRS) has a market capitalization of approximately
AirSculpt Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
AirSculpt Technologies runs a net profit margin of -7.4%, a gross margin of 60.6%, and an operating margin of -7.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
AirSculpt Technologies reported revenue of
AirSculpt Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
AirSculpt Technologies carries a debt-to-equity ratio of 0.71x and a current ratio of 0.75x, with a market beta of 2.37. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For AirSculpt Technologies (AIRS) the key facts are: market cap
Get AirSculpt Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.